| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SGEN Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Rewards
Analysts in good agreement that stock price will rise by 33.2%
Risk Analysis
No risks detected for SGEN from our risk checks.
Seagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$137.72 |
| 52 Week High | US$192.79 |
| 52 Week Low | US$105.43 |
| Beta | 0.62 |
| 1 Month Change | -12.49% |
| 3 Month Change | -22.17% |
| 1 Year Change | -16.15% |
| 3 Year Change | 62.91% |
| 5 Year Change | 136.47% |
| Change since IPO | 1,569.33% |
Recent News & Updates
Seagen in licensing deal with Lava Therapeutics for cancer candidate
Seagen Inc. (NASDAQ:SGEN) announced a license agreement with Dutch biotech LAVA Therapeutics N.V. (LVTX) on Monday for preclinical candidate LAVA-1223 which is designed to target epidermal growth factor receptor (EGFR)-expressing solid tumors. Per the terms, SGEN will pay $50M upfront to LAVA to receive an exclusive worldwide license for LAVA-1223 which uses the latter's proprietary Gammabody technology. The deal also includes up to about $650M milestone payments and royalties on future sales in the range of single digits to the mid-teens. Additionally, the agreement gives SGEN, which focuses on antibody-drug conjugates for cancer, exclusive rights of negotiation to apply LAVA's Gammabody platform on up to two additional tumor targets. LVTX shares have added ~113% pre-market in reaction to the deal, and SGEN is trading flat. SGEN, which was rumored to have attracted buyout interest from Merck (MRK), lost in value in recent days as M&A prospects cooled.
Seagen ticks lower as management suggests it could look at acquisitions
Seagen (NASDAQ:SGEN) ticked down 0.3% as management appeared to indicate the biotech company would be looking at acquisitions rather than being acquired. Seagen management is currently presenting at the Morgan Stanley 20th Annual Global Healthcare Conference. "I would not be surprised to see Seagen move forward on some pretty creative and accretive corporate development initiatives," a Seagen executive said at the conference. The comments come after a a Bloomberg report late last month that talks with Merck (MRK) to buy the company have stalled for the time being. The talks are said to have ended over a disagreement on price. Developing story ...
Shareholder Returns
| SGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | 2.9% | -2.0% |
| 1Y | -16.2% | -24.2% | -20.3% |
Return vs Industry: SGEN exceeded the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: SGEN exceeded the US Market which returned -22.1% over the past year.
Price Volatility
| SGEN volatility | |
|---|---|
| SGEN Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SGEN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: SGEN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 2,675 | Roger Dansey | https://www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
| SGEN fundamental statistics | |
|---|---|
| Market Cap | US$25.40b |
| Earnings (TTM) | -US$739.80m |
| Revenue (TTM) | US$1.78b |
14.3x
P/S Ratio-34.3x
P/E RatioIs SGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGEN income statement (TTM) | |
|---|---|
| Revenue | US$1.78b |
| Cost of Revenue | US$1.59b |
| Gross Profit | US$186.14m |
| Other Expenses | US$925.93m |
| Earnings | -US$739.80m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.01 |
| Gross Margin | 10.47% |
| Net Profit Margin | -41.61% |
| Debt/Equity Ratio | 0% |
How did SGEN perform over the long term?
See historical performance and comparison